{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:58Z","timestamp":1787027818466,"version":"build-2736575974"},"reference-count":127,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Initiative for Innovative Medicine","award":["2021-I2M-1-035"],"award-info":[{"award-number":["2021-I2M-1-035"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["32270915"],"award-info":[{"award-number":["32270915"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["U20A20374"],"award-info":[{"award-number":["U20A20374"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["82071791"],"award-info":[{"award-number":["82071791"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["82103319"],"award-info":[{"award-number":["82103319"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2022YFC3602004"],"award-info":[{"award-number":["2022YFC3602004"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["Z221100007922040"],"award-info":[{"award-number":["Z221100007922040"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["CJ20220185"],"award-info":[{"award-number":["CJ20220185"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["CE20215008"],"award-info":[{"award-number":["CE20215008"]}]},{"name":"National Natural Science Foundation of China","award":["2021-I2M-1-035"],"award-info":[{"award-number":["2021-I2M-1-035"]}]},{"name":"National Natural Science Foundation of China","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"National Natural Science Foundation of China","award":["32270915"],"award-info":[{"award-number":["32270915"]}]},{"name":"National Natural Science Foundation of China","award":["U20A20374"],"award-info":[{"award-number":["U20A20374"]}]},{"name":"National Natural Science Foundation of China","award":["82071791"],"award-info":[{"award-number":["82071791"]}]},{"name":"National Natural Science Foundation of China","award":["82103319"],"award-info":[{"award-number":["82103319"]}]},{"name":"National Natural Science Foundation of China","award":["2022YFC3602004"],"award-info":[{"award-number":["2022YFC3602004"]}]},{"name":"National Natural Science Foundation of China","award":["Z221100007922040"],"award-info":[{"award-number":["Z221100007922040"]}]},{"name":"National Natural Science Foundation of China","award":["CJ20220185"],"award-info":[{"award-number":["CJ20220185"]}]},{"name":"National Natural Science Foundation of China","award":["CE20215008"],"award-info":[{"award-number":["CE20215008"]}]},{"name":"National Key Research and Development Program of China","award":["2021-I2M-1-035"],"award-info":[{"award-number":["2021-I2M-1-035"]}]},{"name":"National Key Research and Development Program of China","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"National Key Research and Development Program of China","award":["32270915"],"award-info":[{"award-number":["32270915"]}]},{"name":"National Key Research and Development Program of China","award":["U20A20374"],"award-info":[{"award-number":["U20A20374"]}]},{"name":"National Key Research and Development Program of China","award":["82071791"],"award-info":[{"award-number":["82071791"]}]},{"name":"National Key Research and Development Program of China","award":["82103319"],"award-info":[{"award-number":["82103319"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFC3602004"],"award-info":[{"award-number":["2022YFC3602004"]}]},{"name":"National Key Research and Development Program of China","award":["Z221100007922040"],"award-info":[{"award-number":["Z221100007922040"]}]},{"name":"National Key Research and Development Program of China","award":["CJ20220185"],"award-info":[{"award-number":["CJ20220185"]}]},{"name":"National Key Research and Development Program of China","award":["CE20215008"],"award-info":[{"award-number":["CE20215008"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["2021-I2M-1-035"],"award-info":[{"award-number":["2021-I2M-1-035"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["32270915"],"award-info":[{"award-number":["32270915"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["U20A20374"],"award-info":[{"award-number":["U20A20374"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["82071791"],"award-info":[{"award-number":["82071791"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["82103319"],"award-info":[{"award-number":["82103319"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["2022YFC3602004"],"award-info":[{"award-number":["2022YFC3602004"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["Z221100007922040"],"award-info":[{"award-number":["Z221100007922040"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["CJ20220185"],"award-info":[{"award-number":["CJ20220185"]}]},{"name":"Beijing Municipal Commission of Science and Technology Fund for Innovative Drugs","award":["CE20215008"],"award-info":[{"award-number":["CE20215008"]}]},{"name":"Changzhou Science and Technology Program","award":["2021-I2M-1-035"],"award-info":[{"award-number":["2021-I2M-1-035"]}]},{"name":"Changzhou Science and Technology Program","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"Changzhou Science and Technology Program","award":["32270915"],"award-info":[{"award-number":["32270915"]}]},{"name":"Changzhou Science and Technology Program","award":["U20A20374"],"award-info":[{"award-number":["U20A20374"]}]},{"name":"Changzhou Science and Technology Program","award":["82071791"],"award-info":[{"award-number":["82071791"]}]},{"name":"Changzhou Science and Technology Program","award":["82103319"],"award-info":[{"award-number":["82103319"]}]},{"name":"Changzhou Science and Technology Program","award":["2022YFC3602004"],"award-info":[{"award-number":["2022YFC3602004"]}]},{"name":"Changzhou Science and Technology Program","award":["Z221100007922040"],"award-info":[{"award-number":["Z221100007922040"]}]},{"name":"Changzhou Science and Technology Program","award":["CJ20220185"],"award-info":[{"award-number":["CJ20220185"]}]},{"name":"Changzhou Science and Technology Program","award":["CE20215008"],"award-info":[{"award-number":["CE20215008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system capable of killing virus-infected cells and\/or cancer cells. The commonly used NK cells for therapeutic applications include primary NK cells and immortalized NK cell lines. However, primary NK cell therapy faces limitations due to its restricted proliferation capacity and challenges in stable storage. Meanwhile, the immortalized NK-92 cell line requires irradiation prior to infusion, which reduces its cytotoxic activity, providing a ready-made alternative and overcoming these bottlenecks. Recent improvements in differentiation protocols for iPSC-derived NK cells have facilitated the clinical production of iPSC-NK cells. Moreover, iPSC-NK cells can be genetically modified to enhance tumor targeting and improve the expansion and persistence of iPSC-NK cells, thereby achieving more robust antitumor efficacy. This paper focuses on the differentiation-protocols efforts of iPSC-derived NK cells and the latest progress in iPSC-NK cell therapy. Additionally, we discuss the current challenges faced by iPSC-NK cells and provide an outlook on future applications and developments.<\/jats:p>","DOI":"10.3390\/cells13231976","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:57:08Z","timestamp":1732849028000},"page":"1976","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy"],"prefix":"10.3390","volume":"13","author":[{"given":"Wenhua","family":"Qiao","sequence":"first","affiliation":[{"name":"CAMS Key Laboratory for T Cell and Immunotherapy, State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Dong","sequence":"additional","affiliation":[{"name":"Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy, Changzhou 213000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"CAMS Key Laboratory for T Cell and Immunotherapy, State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China"},{"name":"Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy, Changzhou 213000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhang","sequence":"additional","affiliation":[{"name":"CAMS Key Laboratory for T Cell and Immunotherapy, State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China"},{"name":"Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy, Changzhou 213000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hon.2672","article-title":"Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor\u2013modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia","volume":"37","author":"Ma","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0006-2952(75)90016-7","article-title":"Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines","volume":"24","author":"Turner","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"ref_9","first-page":"1369","article-title":"Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities","volume":"25","author":"Ardenne","year":"1975","journal-title":"Arzneimittelforschung"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-065X.2006.00451.x","article-title":"Human natural killer cell development","volume":"214","author":"Freud","year":"2006","journal-title":"Immunol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.1975.tb01808.x","article-title":"A serum haemagglutinating property dependent upon polycarboxyl groups","volume":"29","author":"Beck","year":"1975","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0006-291X(75)90498-2","article-title":"Metal substitutions incarbonic anhydrase: A halide ion probe study","volume":"66","author":"Smith","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/0006-2952(75)90080-5","article-title":"Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo","volume":"24","author":"Marniemi","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/bi00695a007","article-title":"The influence of pH on the interaction of inhibitors with triosephosphate isomerase and determination of the pKa of the active-site carboxyl group","volume":"14","author":"Hartman","year":"1975","journal-title":"Biochemistry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The Broad Spectrum of Human Natural Killer Cell Diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.smim.2014.02.002","article-title":"Clinical utility of natural killer cells in cancer therapy and transplantation","volume":"26","author":"Knorr","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4049\/jimmunol.164.3.1148","article-title":"Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression","volume":"164","author":"Pittet","year":"2000","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/blood-2012-06-435941","article-title":"Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities","volume":"120","author":"Tel","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Urban, E.M., Li, H., Armstrong, C., Focaccetti, C., Cairo, C., and Pauza, C.D. (2009). Control of CD56 expression and tumor cell cytotoxicity in human V\u03b32V\u03b42 T cells. BMC Immunol., 10.","DOI":"10.1186\/1471-2172-10-50"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1084\/jem.185.3.499","article-title":"Abnormal Development of Intestinal Intraepithelial Lymphocytes and Peripheral Natural Killer Cells in Mice Lacking the IL-2 Receptor \u03b2 Chain","volume":"185","author":"Suzuki","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1074-7613(00)80664-0","article-title":"IL-15 Receptor Maintains Lymphoid Homeostasis by Supporting Lymphocyte Homing and Proliferation","volume":"9","author":"Lodolce","year":"1998","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15\u2013Deficient Mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4049\/jimmunol.174.3.1213","article-title":"Roles for Common Cytokine Receptor \u03b3-Chain-Dependent Cytokines in the Generation, Differentiation, and Maturation of NK Cell Precursors and Peripheral NK Cells In Vivo","volume":"174","author":"Vosshenrich","year":"2005","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Shin, E., Bak, S.H., Park, T., Kim, J.W., Yoon, S.-R., Jung, H., and Noh, J.-Y. (2023). Understanding NK cell biology for harnessing NK cell therapies: Targeting cancer and beyond. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1192907"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1615\/CritRevImmunol.2014010604","article-title":"NK Cells and Their Ability to Modulate T Cells during Virus Infections","volume":"34","author":"Cook","year":"2014","journal-title":"Crit. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or Adaptive Immunity? The Example of Natural Killer Cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"ref_31","first-page":"929","article-title":"Role of Natural Killer Cells in Tumor Growth and Metastasis: C57BL\/6 Normal and Beige Mice23","volume":"65","author":"Talmadge","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/imt.09.47","article-title":"Safety Analysis of Ex Vivo -Expanded NK and NK-Like T Cells Administered to Cancer Patients: A Phase I Clinical Study","volume":"1","author":"Barkholt","year":"2009","journal-title":"Immunotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/1078-0432.CCR-03-0683","article-title":"Treatment of Colon and Lung Cancer Patients with Ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells","volume":"10","author":"Krause","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mantovani, S., Oliviero, B., Varchetta, S., Mele, D., and Mondelli, M.U. (2020). Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers, 12.","DOI":"10.3390\/cancers12040926"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1054-3589(04)51013-X","article-title":"Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma","volume":"Volume 51","author":"Farag","year":"2004","journal-title":"Advances in Pharmacology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.4049\/jimmunol.164.6.3330","article-title":"IFN-\u03b3-Dependent and -Independent Mechanisms in Adverse Effects Caused by Concomitant Administration of IL-18 and IL-12","volume":"164","author":"Nakamura","year":"2000","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_43","first-page":"914945","article-title":"Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas","volume":"2010","author":"Porrata","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients with Cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical Natural Killer Cells Infused Before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lim, O., Jung, M.Y., Hwang, Y.K., and Shin, E.-C. (2015). Present and Future of Allogeneic Natural Killer Cell Therapy. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00286"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","article-title":"Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors","volume":"6","author":"Oei","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"24801","DOI":"10.18632\/oncotarget.24835","article-title":"Prognostic significance of immune cells in non-small cell lung cancer: Meta-analysis","volume":"9","author":"Soo","year":"2018","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tang, Y., Xie, M., Li, K., Li, J., Cai, Z., and Hu, B. (2020). Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-1177-8"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1172\/JCI132712","article-title":"Pembrolizumab plus allogeneic NK cells in advanced non\u2013small cell lung cancer patients","volume":"130","author":"Lin","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mikulak, J., Bruni, E., Oriolo, F., Di Vito, C., and Mavilio, D. (2019). Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00946"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","article-title":"Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation","volume":"15","author":"Berjis","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","article-title":"The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells","volume":"147","author":"Verneris","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Human Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mehta, R.S., Shpall, E.J., and Rezvani, K. (2016). Cord Blood as a Source of Natural Killer Cells. Front. Med., 2.","DOI":"10.3389\/fmed.2015.00093"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhao, X., Cai, L., Hu, Y., and Wang, H. (2020). Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.584099"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: An \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematotherapy Stem Cell Res."},{"key":"ref_70","first-page":"486","article-title":"Immunization against Q-fever of naturally infected dairy cows","volume":"19","author":"Brezina","year":"1975","journal-title":"Acta Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.21873\/anticanres.14543","article-title":"Human NK-92 Cells Function as Target Cells for Human NK Cells\u2014Implications for CAR NK-92 Therapies","volume":"40","author":"Bergman","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stemcr.2014.01.014","article-title":"Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells","volume":"2","author":"Valamehr","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Goldenson, B.H., Zhu, H., Wang, Y.M., Heragu, N., Bernareggi, D., Ruiz-Cisneros, A., Bahena, A., Ask, E.H., Hoel, H.J., and Malmberg, K.-J. (2020). Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.561553"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Larbi, A., Gombert, J.-M., Auvray, C., l\u2019Homme, B., Magniez, A., F\u00e9raud, O., Coulombel, L., Chapel, A., Mitjavila-Garcia, M.T., and Turhan, A.G. (2012). The HOXB4 Homeoprotein Promotes the Ex Vivo Enrichment of Functional Human Embryonic Stem Cell-Derived NK Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039514"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/JVI.01774-10","article-title":"Human Pluripotent Stem Cells Produce Natural Killer Cells That Mediate Anti-HIV-1 Activity by Utilizing Diverse Cellular Mechanisms","volume":"85","author":"Ni","year":"2011","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Bock, A.M., Knorr, D., and Kaufman, D.S. (2013). Development, Expansion, and In vivo Monitoring of Human NK Cells from Human Embryonic Stem Cells (hESCs) and Induced Pluripotent Stem Cells (iPSCs). JoVE, e50337.","DOI":"10.3791\/50337-v"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.devcel.2020.02.016","article-title":"Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors During Mammalian Development","volume":"53","author":"Dege","year":"2020","journal-title":"Dev. Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/stem.1611","article-title":"Expression of Chimeric Receptor CD4 \u03b6 by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo","volume":"32","author":"Ni","year":"2014","journal-title":"Stem Cells"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mesquitta, W.-T., Wandsnider, M., Kang, H., Thomson, J., Moskvin, O., Suknuntha, K., and Slukvin, I.I. (2019). UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-43054-4"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of \u201cOff-the-Shelf\u201d Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells","volume":"9","author":"Zeng","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.14348\/molcells.2021.0078","article-title":"iPSC-Derived Natural Killer Cells for Cancer Immunotherapy","volume":"44","author":"Karagiannis","year":"2021","journal-title":"Mol. Cells"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells","volume":"Volume 2048","author":"Kaneko","year":"2019","journal-title":"In Vitro Differentiation of T-Cells"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2019-131138","article-title":"FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab","volume":"134","author":"Bjordahl","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2019-129319","article-title":"FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2021.39.15_suppl.7541","article-title":"Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed\/refractory (R\/R) B-cell lymphoma (BCL)","volume":"39","author":"Strati","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: A non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/blood-2002-11-3392","article-title":"IL-15 is an essential mediator of peripheral NK-cell homeostasis","volume":"101","author":"Ranson","year":"2003","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1073\/pnas.95.1.114","article-title":"Twenty proteins containing a C-terminal SOCS box form five structural classes","volume":"95","author":"Hilton","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1267892","DOI":"10.1080\/2162402X.2016.1267892","article-title":"Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis","volume":"6","author":"Putz","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Della Chiesa, M., Falco, M., Muccio, L., Bertaina, A., Locatelli, F., and Moretta, A. (2013). Impact of HCMV Infection on NK Cell Development and Function after HSCT. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00458"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","article-title":"Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia","volume":"29","author":"Chiu","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer Cytokines: Biology and Clinical Effects of Interferon-\u03b12, Interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"ref_103","first-page":"314P","article-title":"Proceedings: Evaluation of narcotic and narcotic antagonist analgesic drugs in the dog dental pulp stimulation test","volume":"55","author":"Marriott","year":"1975","journal-title":"Br. J. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4049\/jimmunol.1203034","article-title":"Antibody-dependent memory-like NK cells distinguished by FcR\u03b3-deficiency","volume":"190","author":"Zhang","year":"2013","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.4049\/jimmunol.1402281","article-title":"Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus","volume":"194","author":"Vera","year":"2015","journal-title":"J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: The effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Xie, G., Dong, H., Liang, Y., Ham, J.D., Rizwan, R., and Chen, J. (2020). CAR-NK cells: A promising cellular immunotherapy for cancer. eBioMedicine, 59.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/cas.14374","article-title":"Non\u2013clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti\u2013glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1158\/1538-7445.AM2020-3313","article-title":"Abstract 3313: iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma","volume":"80","author":"Yu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen\u2013targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Lin, X., Guan, T., Li, Y., Lin, Y., Huang, G., Lin, Y., Sun, P., Li, C., Gu, J., and Zeng, H. (2024). Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1337557"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT, a novel immune checkpoint in human cancers (Review)","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","article-title":"synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy","volume":"15","author":"Lupo","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2019-131373","article-title":"FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma","volume":"134","author":"Bjordahl","year":"2019","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2018-99-116459","article-title":"CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab","volume":"132","author":"Woan","year":"2018","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2022-167139","article-title":"Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy","volume":"140","author":"Williams","year":"2022","journal-title":"Blood"},{"key":"ref_121","unstructured":"(2024, August 09). Available online: https:\/\/fatetherapeutics.com\/pipeline\/immuno-oncology-candidates\/ft522\/."},{"key":"ref_122","unstructured":"(2024, August 09). Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates. Available online: https:\/\/investors.centurytx.com\/news-releases\/news-release-details\/century-therapeutics-present-63rd-american-society-hematology\/."},{"key":"ref_123","unstructured":"Sava, J. (2022). FDA Clears Ind for Cnty-101 in Relapsed\/Refractory CD19 Positive B-cell Malignancies."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Doss, M.X., and Sachinidis, A. (2019). Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. Cells, 8.","DOI":"10.3390\/cells8050403"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/rme.12.51","article-title":"Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells","volume":"7","author":"Knoepfler","year":"2012","journal-title":"Regen. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","article-title":"CRISPR-Cas9 for cancer therapy: Opportunities and challenges","volume":"447","author":"Chen","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymgme.2021.08.002","article-title":"Current advances in overcoming obstacles of CRISPR\/Cas9 off-target genome editing","volume":"134","year":"2021","journal-title":"Mol. Genet. Metab."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/23\/1976\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:42:18Z","timestamp":1760114538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/23\/1976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":127,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cells13231976"],"URL":"https:\/\/doi.org\/10.3390\/cells13231976","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}